Philippe L. Bédard

2009–2026 年に発表

別表記
Philippe L. Bedard
155
論文数
18,618
被引用数
66
h 指数
136
i10 指数

被引用数

Philippe L. Bédard の年別被引用数1992 年: 被引用 1 件2003 年: 被引用 1 件2004 年: 被引用 1 件2010 年: 被引用 14 件2011 年: 被引用 10 件2012 年: 被引用 37 件2013 年: 被引用 64 件2014 年: 被引用 88 件2015 年: 被引用 101 件2016 年: 被引用 131 件2017 年: 被引用 137 件2018 年: 被引用 148 件2019 年: 被引用 615 件2020 年: 被引用 908 件2021 年: 被引用 1,096 件2022 年: 被引用 1,042 件2023 年: 被引用 876 件2024 年: 被引用 1,271 件2025 年: 被引用 729 件2026 年: 被引用 23 件1993〜2002 年は被引用が無いため表示していません2005〜2009 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,886 件、この内訳の 24%中国: 引用元論文 1,318 件、この内訳の 11%イタリア: 引用元論文 800 件、この内訳の 6.6%イギリス: 引用元論文 721 件、この内訳の 6%カナダ: 引用元論文 582 件、この内訳の 4.8%ドイツ: 引用元論文 579 件、この内訳の 4.8%フランス: 引用元論文 519 件、この内訳の 4.3%スペイン: 引用元論文 457 件、この内訳の 3.8%スイス: 引用元論文 310 件、この内訳の 2.6%オーストラリア: 引用元論文 307 件、この内訳の 2.6%オランダ: 引用元論文 306 件、この内訳の 2.5%日本: 引用元論文 289 件、この内訳の 2.4%
0%24%その他 24.6%

分野

  • Medicine51.1%
  • Biochemistry, Genetics and Molecular Biology40.3%
  • Immunology and Microbiology2.7%
  • Computer Science1.4%
  • Engineering0.9%
  • Materials Science0.6%
  • その他3%

トピック

  • Cancer Genomics and Diagnostics8.2%
  • Cancer Immunotherapy and Biomarkers5.7%
  • Lung Cancer Treatments and Mutations3.4%
  • HER2/EGFR in Cancer Research2.6%
  • Advanced Breast Cancer Therapies2.2%
  • Cancer Cells and Metastasis2.2%
  • その他75.7%

共著者

全論文

検索で開く
  1. AACR Project GENIE: Powering Precision Medicine through an International Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefèbvre, Michele L. Lenoue-Newton, Eva M. Lepisto, Mia Levy, Neal I. Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E. MacConaill, Ian Maurer, David S. Maxwell, Gerrit A. Meijer, Funda Meric‐Bernstam, Christine Micheel, Clinton Miller, Gordon B. Mills, Nathanael D. Moore, Petra M. Nederlof, Larsson Omberg, John A. Orechia, Ben Ho Park, Trevor J. Pugh, Brendan Reardon, Barrett J. Rollins, Mark J. Routbort, Charles L. Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna Shaw, Priyanka Shivdasani, Lillian L. Siu, David B. Solit, Gabe S. Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie Stickle, Thomas Stricker, Shawn M. Sweeney, Barry S. Taylor, Jelle J. ten Hoeve, Stacy B. Thomas, Eliezer M. Van Allen, Laura van ‘t Veer, Tony van de Velde, Harm van Tinteren, Victor E. Velculescu, Carl Virtanen, Emile E. Voest, Lucy Lu Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang - Cancer Discovery 2017 被引用: 2,004

  2. Sensitive tumour detection and classification using plasma cell-free DNA methylomes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark D. Minden, Steven Gallinger, Anna Goldenberg, Trevor J. Pugh, Michael M. Hoffman, Scott V. Bratman, Rayjean J. Hung, Daniel D. De Carvalho - Nature 2018 被引用: 1,040

  3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2018 被引用: 787

  4. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 348

  5. Small molecules, big impact: 20 years of targeted therapy in oncology

    著者: , , , - The Lancet 2020 被引用: 602

  6. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2020 被引用: 480

  7. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 549

  8. Tumour heterogeneity in the clinic

    著者: , , , - Nature 2013 被引用: 1,230

  9. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2022 被引用: 197

  10. Novel patterns of response under immunotherapy

    著者: , , , , , , , , - Annals of Oncology 2019 被引用: 511

  11. A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors

    著者: , , , , , , , , , , - American Journal of Clinical Oncology 2020 被引用: 250

  12. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Samuel Aparício, David W. Cescon - Nature Communications 2022 被引用: 145

  13. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 387

  14. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martina Degiorgis, Silvia Khodaverdi, Richard Greil, Ásgerður Sverrisdóttir, Marta Paoli, Ethel Seyll, Sibylle Loibl, Barbro Linderholm, Gabriele Zoppoli, Nancy E. Davidson, Oskar T. Johannsson, Philippe L. Bédard, Sherene Loi, Susan Knox, David Cameron, Nadia Harbeck, Maite Lasa Montoya, Mariana Brandão, Andrea Vingiani, Carmela Caballero, Florentine Hilbers, Lucy Yates, Matteo Benelli, David Venet, Martine Piccart - Cancer Discovery 2021 被引用: 177

  15. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2023 被引用: 63

  16. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 102

  17. OncoTree: A Cancer Classification System for Precision Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah P. Suehnholz, Moriah H. Nissan, Gopa Iyer, Rajmohan Murali, Nancy Bouvier, Robert A. Soslow, David M. Hyman, Anas Younes, Andrew M. Intlekofer, James J. Harding, Richard D. Carvajal, Paul Sabbatini, Ghassan K. Abou‐Alfa, Luc G.T. Morris, Yelena Y. Janjigian, Meighan M. Gallagher, Tara A. Soumerai, Ingo K. Mellinghoff, A. Ari Hakimi, Matthew G. Fury, Jason T. Huse, Aditya Bagrodia, Meera Hameed, Stacy B. Thomas, Stuart M. Gardos, Ethan Cerami, Tali Mazor, Priti Kumari, Pichai Raman, Priyanka Shivdasani, Suzanne P. MacFarland, Scott Newman, Angela J. Waanders, Jianjiong Gao, David B. Solit, Nikolaus Schultz - JCO Clinical Cancer Informatics 2021 被引用: 150

  18. A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2014 被引用: 326

  19. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2017 被引用: 146

  20. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

    著者: , , , , , , , , , , , - Annals of Oncology 2022 被引用: 81

  21. Leveraging big data of immune checkpoint blockade response identifies novel potential targets

    著者: , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 81

  22. AKT Inhibition in Solid Tumors With AKT1 Mutations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José Baselga, Barry S. Taylor - Journal of Clinical Oncology 2017 被引用: 325

  23. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 128

  24. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

    著者: , , , , , , , , , , , , - Investigational New Drugs 2015 被引用: 170